This guidance will fully update the following:
 
Status In progress
Process MTA
ID number 809

Project Team

Project lead Jeremy Powell

Email enquiries

Consultees

Companies sponsors Bayer
  Biogen Idec
  Merck Serono
  Novartis
  Teva Pharmaceuticals
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Multiple Sclerosis Society
  Multiple Sclerosis Trust
Professional groups Association of British Neurologists
  Royal College of Physicians
  United Kingdom Clinical Pharmacy Association
  United Kingdom Multiple Sclerosis Specialist Nurse Association

Commentators

Comparator companies * included on the matrix because NICE has recommended their products in related technology appraisals. It is not intended that these products will be comparators in the current appraisal.
  Biogen Idec (dimethyl fumarate, natalizumab)
  Genzyme (alemtuzumab, teriflunomide)
  Novartis (fingolimod)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland

Timeline

Key events during the development of the guidance:

Date Update
07 July 2017 Following the Appraisal Committee meeting on this for ‘Beta interferons and glatiramer acetate for treating multiple sclerosis [ID809]’ on 23 May, we are pausing this appraisal. From discussions with the companies we understand that several are considering access agreements for their technologies, which means that the basis for the decision making is likely to change. NICE is committed to working towards a solution that ensures patients with multiple sclerosis continue to have access to beta-interferons and glatiramer acetate. We therefore do not consider it appropriate to release an ACD at this stage. We will provide an update on the future timelines as soon as we can.
23 May 2017 Committee meeting: 2
25 November 2016 The MTA ‘Multiple sclerosis - interferon beta, glatiramer acetate (review TA32) [ID809]’ has been suspended to allow NICE to reconcile the submissions made by stakeholders and the Assessment Group with the committee’s preferred assumptions.
02 November 2016 Committee meeting: 1
06 September 2016 Assessment report sent for information
15 February 2016 Draft scope documents
15 February 2016 Invitation to participate
15 February 2016 The final scope and comments table for this appraisal have been reissued. Following their release earlier this month NICE has received notification of an error in the scope relating to the marketing authorisation of one of the technologies under consideration. NICE has also been made aware that, due to an administrative error, some consultation comments were excluded from consideration. The scope and comments table have therefore been updated to address the comments and correct the error.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance